Viral Vector Vaccines Market to Reach 14% CAGR through 2031, Driven by Advances in Gene Therapy and Rapid Vaccine Development | DataM Intelligence

According to DataM Intelligence, the global Viral Vector Vaccines market is expected to grow at a CAGR of 14% during the forecast period 2024-2031, driven by increasing applications in gene therapy and vaccinology, strong demand for adeno-associated virus and adenovirus vectors, growing use of intramuscular and subcutaneous routes, expanding distribution through hospitals and vaccination centers.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/viral-vector-vaccines-market?jd

Key Mergers and Acquisitions

✦ January 2026: AstraZeneca acquired a viral vector platform startup to enhance its gene therapy and vaccine development capabilities for oncology and infectious diseases.
✦ December 2025: Sanofi Pasteur Inc. completed a strategic acquisition of a gene delivery technology firm to strengthen its adenovirus and AAV vector portfolio for vaccinology.
✦ November 2025: BioNTech secured a licensing agreement with an advanced viral vector innovator to integrate novel lentivirus and Sendai virus platforms into its mRNA and gene therapy pipeline.

United States Key Industry Developments

☑️ January 2026: AstraZeneca and Pfizer expanded U.S. availability of viral vector-based vaccine platforms with new clinical data supporting broader indications in oncology and infectious diseases.
☑️ January 2026: Sanofi Pasteur Inc. reported strong adoption of adenovirus and AAV vector technologies in vaccine development pipelines, securing additional NIH funding for next-generation candidates.
☑️ December 2025: GlaxoSmithKline Plc advanced its viral vector vaccine programs with updated Phase II results for respiratory and viral disease targets, gaining traction in U.S. vaccination centers.

Japan Key Industry Developments

☑️ January 2026: Japanese biotech firms accelerated regulatory filings for viral vector vaccines, supported by updated PMDA guidelines for gene therapy and vaccinology applications.
☑️ January 2026: Local and global players showcased advanced AAV and lentivirus vector technologies at major Tokyo biotech conferences, emphasizing safety and efficacy in rare disease and cancer treatments.
☑️ December 2025: Growing integration of viral vector platforms in Japan's hospitals and specialized clinics, driven by demand for precision gene therapies and next-generation immunization programs.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=viral-vector-vaccines-market

Market Segmentation Analysis

By Vector Type: Adeno-associated virus (AAV) holds the largest share due to its safety profile, long-term expression, and widespread use in gene therapy and vaccinology; Adenovirus follows for high immunogenicity in vaccine development; Lentivirus and Retrovirus grow steadily for stable gene integration; Sendai virus expands in respiratory-targeted applications.

By Route of Administration: Intramuscular dominates with established use in vaccine delivery and systemic gene therapy; Subcutaneous grows rapidly for localized and convenient administration in certain therapies.

By Application: Gene Therapy accounts for the highest share with focus on rare diseases and oncology; Vaccinology Development grows fastest for prophylactic and therapeutic viral vector vaccines; Others include regenerative medicine and immunotherapy.

By Distribution Channel: Hospitals lead for specialized administration and monitoring of gene therapies; Vaccination Centers follow for mass immunization campaigns; Specialized Clinics expand for targeted therapies; Others include research institutions and outpatient facilities.

Regional Insights

North America commands the largest market share in the global Viral Vector Vaccines market, supported by advanced gene therapy infrastructure, high regulatory approvals for AAV and adenovirus vectors, strong R&D investment in vaccinology and oncology, widespread clinical trial activity, and presence of leading biotech and pharmaceutical companies driving innovation.
Asia-Pacific remains the fastest-growing region, fueled by rising healthcare investments in China, India, and Japan, increasing focus on gene therapy and vaccine development, expanding manufacturing capabilities for viral vectors, government support for biotechnology, and growing clinical adoption of AAV-based therapies for rare diseases and cancer.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/viral-vector-vaccines-market?jd

Key Players

The market includes major global players such as Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca, CSL Ltd. (Seqirus), Abbott, GlaxoSmithKline Plc, Serum Institute of India Pvt. Ltd, Pfizer, BioNTech, F.Hoffman La Roche Ltd, Novartis, and others.

Key Highlights (Top 5 Key Players)

✦ Sanofi Pasteur Inc. (Sanofi S/A) - Leading developer of viral vector vaccines with strong focus on adenovirus platforms for infectious diseases and oncology applications.
✦ AstraZeneca - Renowned for viral vector technologies in vaccine development, with established programs in respiratory and viral disease targets.
✦ Pfizer - Dominant in innovative viral vector platforms, advancing gene therapy and prophylactic vaccines for multiple indications.
✦ GlaxoSmithKline Plc - Strong presence in vaccinology with viral vector-based candidates for infectious diseases and cancer immunotherapy.
✦ BioNTech - Innovating in viral vector delivery systems, leveraging mRNA and vector technologies for oncology and infectious disease vaccines.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.